|
시장보고서
상품코드
2008135
메토트렉세이트 제제 시장 : 치료 유형별, 투여 경로별, 유통 채널별, 지역별Methotrexate Drugs Market, By Treatment Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
메토트렉세이트 제제 시장은 2026년에 6억 5,260만 달러로 추계되고 있으며, 2033년까지 7억 4,360만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 2.6%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 6억 5,260만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 2.60% | 예측 금액(2033년) | 7억 4,360만 달러 |
메토트렉세이트는 질병조절형 항류마티스제제(DMARD)의 일종입니다. 특정 질환을 앓고 있는 환자의 면역계 활동을 억제하는 데 사용됩니다. 일반적으로 면역계는 염증을 일으켜 감염과 싸우는 방식으로 신체를 보호합니다. 염증은 부종, 열감, 발적, 통증을 유발할 수 있습니다. 메토트렉세이트는 정제, 액상 또는 주사제 형태로 제공됩니다. 메토트렉세이트 정제는 2.5mg과 10mg 두 가지 용량이 있습니다. 메토트렉세이트는 체내 특정 세포, 특히 암세포, 골수세포, 피부세포 등 빠르게 증식하는 세포의 성장을 억제합니다.
시장 역학
시장의 주요 기업은 메토트렉세이트 제제 개발을 위한 연구개발 활동에 전념하고 있으며, 이는 예측 기간 중 글로벌 메토트렉세이트 제제 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2019년 6월 화이자는 중등도에서 중증의 류마티스관절염(RA) 성인 환자를 대상으로 한 3b/4상 임상 3b/4상 시험인 'ORAL Shift'에서 좋은 결과를 발표했습니다. 24주간의 오픈 라벨 도입 기간 후, XELJANZ(토파시티닙) 서방형 제제(XR) 11mg 1일 1회(QD)와 메토트렉세이트(MTX) 병용요법으로 저질병활성도(LDA)를 달성한 환자들을 무작위 배정하여 MTX 중단 후 XELJANZ XR 11mg QD 단독요법의 유효성과 안전성을 MTX 지속 병용투여시 XELJANZ XR 11mg QD 단독요법의 유효성과 안전성을 비교 평가했습니다.
조직의 인식 제고 활동, 관절염 유병률 증가, 제품 출시 등의 요인이 글로벌 메토트렉세이트 제제 시장의 성장을 주도하고 있습니다. 예를 들어 2018년 5월, Hikma Pharmaceuticals PLC는 자사의 완전 자회사인 미국 West-Ward Pharmaceuticals Corp. USP)를 출시했다고 밝혔습니다. 시장 기업의 이러한 노력은 예측 기간 중 글로벌 메토트렉세이트 제제 시장의 성장을 촉진할 것으로 예상됩니다. 또한 관절염과 암에 대한 여러 유망한 약물이 파이프라인에 있으며, 이는 글로벌 메토트렉세이트 제제 시장의 성장을 촉진할 것으로 예상됩니다.
이 보고서의 주요 특징
- 세계의 메토트렉세이트 제제 시장을 상세히 분석하고, 2021년을 기준연도로 하여 예측 기간(2022-2030년) 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트를 제공합니다.
- 세계의 메토트렉세이트 제제 시장의 주요 기업 개요을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 정리하여 제공합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계의 메토트렉세이트 제제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 메토트렉세이트 제제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 메토트렉세이트 제제 시장 : 치료 유형별(2026-2033년)
제5장 세계의 메토트렉세이트 제제 시장 : 투여 경로별(2026-2033년)
제6장 세계의 메토트렉세이트 제제 시장 : 유통 채널별(2026-2033년)
제7장 세계의 메토트렉세이트 제제 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSA 26.04.30Methotrexate Drugs Market is estimated to be valued at USD 652.6 Mn in 2026 and is expected to reach USD 743.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 2.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 652.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 2.60% | 2033 Value Projection: | USD 743.6 Mn |
Methotrexate is a type of disease-modifying anti-rheumatic drug (DMARD). It is used to reduce the activity of the immune system for people who have certain conditions. The immune system normally protects the body from infections by causing inflammation to fight them. Inflammation can cause swelling, heat, redness and pain. Methotrexate is available in tablet, liquid or injection form. Methotrexate tablets come in two strengths: 2.5 mg and 10 mg. Methotrexate interferes with the growth of certain cells of the body, especially cells that reproduce quickly, such as cancer cells, bone marrow cells, and skin cells.
Market Dynamics
Key players in market are involved in research and development activities to develop Methotrexate drugs which is expected to drive the growth of global methotrexate drugs market over the forecast period. For instance, in June 2019, Pfizer Inc., announced positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA). Patients who achieved low disease activity (LDA) with XELJANZ (tofacitinib) extended release (XR) 11 mg once daily (QD) plus methotrexate (MTX) after a 24-week open-label run-in period, were randomized to evaluate the efficacy and safety of XELJANZ XR 11 mg QD as monotherapy after MTX withdrawal compared with XELJANZ XR with continued MTX.
Factors such as awareness initiatives by organizations, increasing prevalence of Arthritis, and product launches are driving the global methotrexate drugs market growth. For instance, in May 2018, Hikma Pharmaceuticals PLC., announced that it is wholly owned U.S. subsidiary West-Ward Pharmaceuticals Corp., has launched Methotrexate for Injection, USP in a 1g preservative-free presentation and Methotrexate Injection, USP 50mg/2mL, 2 mL vials. Such initiatives by market players are expected to boost the global methotrexate drugs market growth over the forecast period. Moreover, pipeline for Arthtitis, cancers has several potential medications, which is expected to drive global methotrexate drugs market growth.
Key features of the study
- This report provides an in-depth analysis of the global methotrexate drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global methotrexate drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include LEO Pharma A/S, Bristol Myers Squibb, Nordic Pharma, Eli Lilly and Company, Horizon Therapeutics plc., Cumberland Pharmaceuticals Inc., Azurity Pharmaceuticals, Inc., Pfizer Inc., Hikma Pharmaceuticals PLC., and Onco Therapies Limited (Strides Arcolab Limited).
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global methotrexate drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global methotrexate drugs market.
Market Segmentation
- Global Methotrexate Drugs Market, By Treatment Type
- Psoriasis
- Rheumatoid Arthritis
- Cancer
- Global Methotrexate Drugs Market, By Route of Administration
- Oral
- Injection
- Global Methotrexate Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Methotrexate Drugs Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- LEO Pharma A/S
- Bristol Myers Squibb
- Nordic Pharma
- Eli Lilly and Company
- Horizon Therapeutics plc.
- Cumberland Pharmaceuticals Inc.
- Azurity Pharmaceuticals, Inc.
- Pfizer Inc.
- Hikma Pharmaceuticals PLC.
- Onco Therapies Limited (Strides Arcolab Limited)
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- New Drug Launch
- Key Highlights
- Research and Development Collaboration, Mergers, and Acquisitions
- PEST Analysis
- Pipeline Analysis
- Epidemiology
4. Global Methotrexate Drugs Market, By Treatment Type, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Psoriasis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Rheumatoid Arthritis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Global Methotrexate Drugs Market, By Route Of Administration, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Injection
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Global Methotrexate Drugs Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Global Methotrexate Drugs Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- LEO Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol Myers Squibb
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nordic Pharma
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Horizon Therapeutics plc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cumberland Pharmaceuticals Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Azurity Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Onco Therapies Limited (Strides Arcolab Limited)
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LEO Pharma A/S
9. Section
- References
- Research Methodology
- About Us and Sales Contact
